Table 2.
CYP3A4 polymorphisms genotyped in 273 patients
| SNP | Alleles | Location | All Patients, n = 273
|
Caucasian, n = 243
|
Non-Caucasian, n = 30
|
|||
|---|---|---|---|---|---|---|---|---|
| MAF | HWE P | MAF | HWE P | MAF | HWE P | |||
| rs34401238 | TGT Del/Ins | CYP3A4 enhancer | 0.016 | 0.78 | 0.017 | 0.79 | 0.018 | 0.92 |
| rs2740574 | A>G, *1B | CYP3A4 promoter | 0.105 | 6.06E–07 | 0.054 | 0.71 | 0.350 | 0.77 |
| rs35599367 | C>T | CYP3A4 intron 6 | 0.047 | 0.061 | 0.052 | 0.08 | 0 | NA |
| rs4987161 | T>C, *17 | CYP3A4 exon 7 | 0 | NA | 0 | NA | 0 | NA |
| rs28371759 | T>C, *18 | CYP3A4 exon 10 | 0 | NA | 0 | NA | 0 | NA |
| rs776746 | G>A, *3 | CYP3A5 intron 3 | 0.138 | 2.81E–08 | 0.088 | 0.09 | 0.376 | 0.28 |
| rs1303343 | T Del/Ins, *7 | CYP3A5 exon 11 | 0.012 | 4.53E–06 | 0.008 | 0.95 | 0.055 | 0.76 |
Abbreviations: HWE, Hardy–Weinberg equilibrium; MAF, minor allele frequency; SNP, single nucleotide polymorphism.